Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Feb 4;17(2):e0263788. doi: 10.1371/journal.pone.0263788

Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group study

Celmira Laza-Vásquez 1,2, Núria Codern-Bové 3,4,5, Àngels Cardona-Cardona 5, Maria José Hernández-Leal 6,7, Maria José Pérez-Lacasta 6,7, Misericòrdia Carles-Lavila 6,7, Montserrat Rué 8,9,*; on behalf of the DECIDO group
Editor: Eugenio Paci10
PMCID: PMC8815913  PMID: 35120169

Abstract

Background

With the aim of increasing benefits and decreasing harms, risk-based breast cancer screening has been proposed as an alternative to age-based screening. This study explores barriers and facilitators to implementing a risk-based breast cancer screening program from the perspective of health professionals, in the context of a National Health Service.

Methods

Socio-constructivist qualitative research carried out in Catalonia (Spain), in the year 2019. Four discussion groups were conducted, with a total of 29 health professionals from primary care, breast cancer screening programs, hospital breast units, epidemiology units, and clinical specialties. A descriptive-interpretive thematic analysis was performed.

Results

Identified barriers included resistance to reducing the number of screening exams for low-risk women; resistance to change for health professionals; difficulties in risk communication; lack of conclusive evidence of the benefits of risk-based screening; limited economic resources; and organizational transformation. Facilitators include benefits of risk-based strategies for high and low-risk women; women’s active role in their health care; proximity of women and primary care professionals; experience of health professionals in other screening programs; and greater efficiency of a risk-based screening program. Organizational and administrative changes in the health system, commitment by policy makers, training of health professionals, and educational interventions addressed to the general population will be required.

Conclusions

Despite the expressed difficulties, participants supported the implementation of risk-based screening. They highlighted its benefits, especially for women at high risk of breast cancer and those under 50 years of age, and assumed a greater efficiency of the risk-based program compared to the aged-based one. Future studies should assess the efficiency and feasibility of risk-based breast cancer screening for its transfer to clinical practice.

Introduction

Breast cancer is the most common cancer in women and overall. In 2020, more than 2.2 million new cases were diagnosed, representing 11.7% of all cancer cases. Breast cancer was the leading cause of cancer deaths in women with 68,000 deaths worldwide. In Spain, in 2020, the estimated numbers of incident cases and breast cancer deaths in women were 34,000 and 6,600, respectively [1].

Screening programs are one of the pillars in the fight against breast cancer, they aim to reduce mortality from this cause through early detection and treatment. However, there is evidence that screening may cause harm, e.g. false positive and false negative results or overdiagnosis of tumors that would otherwise not go on to cause symptoms or death [2], leading to negative consequences for women and economic consequences for health systems [3, 4].

Current population-based screening programs use age as the only condition to define the target population. With the aim of increasing benefits and decreasing harms, risk-based screening has been proposed as an alternative to age-based screening. Age, breast density, family history of breast cancer, previous benign lesions and genetic information have been the main risk factors used to define risk groups [5, 6]. Yanes et al. [7] showed that, in European populations, the addition of a PRS to the existing risk models improved their accuracy and predictive ability. Evans et al. [8] added a PRS and mammographic density to the Tyrer-Cuzick model, with the objective of enabling more targeted early detection/prevention strategies in population screening programs. The combined risk tool defined a low-risk group, about 30% of the total, such that cancers identified in this group were more likely to have a very good prognosis.

Although evidence of the effectiveness of risk-based screening from clinical trials is not available yet, a systematic review that included nine modeling studies and an observational study showed that with personalized screening, the gain in quality adjusted life years would be higher at a lower cost, compared with the standard age-based strategy [9]. However, evidence is lacking on feasibility and acceptance by the target population. French et al. [10] developed an automated system (BC-Predict) for offering an assessment of breast cancer risk and communication to women and health professionals. The study aimed to identify and resolve key uncertainties regarding the feasibility of integrating BC-Predict into the breast screening program in England. Pons-Rodriguez et al. recently published the protocol of a proof-of-concept study on feasibility and acceptability of personalized breast cancer screening in Catalonia (Spain) [11].

Although risk-based breast cancer screening seems promising, it is expected that its implementation as a population-wide screening will pose complex issues and will require the involvement of healthcare professionals. In addition, in a context of uncertainty where health professionals with clinical expertise have access to the best evidence and women have their experiences, values and preferences, it seems necessary to move from a paternalistic to a participatory style of care [12]. Shared decision-making would facilitate participatory decisions in clinical encounters where health professionals would explain, in a balanced way, the benefits and harms of screening [13] and provide risk-based screening recommendations.

Several studies have addressed the perspectives of health professionals on risk-based screening [1419]. These works have described barriers such as the need for more evidence on effectiveness and efficiency [14], concerns about the capacity of the healthcare system to provide appropriate human resources, economic costs, lack of knowledge among healthcare providers [15], time constraints, low health literacy and language barriers to risk communication [18].

The organization of the Spanish National Health Service (SpNHS) is decentralized in 17 regions with screening guidelines set by the local governments and coordinated by the Network of Cancer Screening Programs and the Ministry of Health [20]. Most of the screening programs target women aged 50–69 years and perform biennial mammograms. However, opportunistic screening in women younger than 50 years is widely used, mostly in private consultations. Including women younger than 50 years in risk-based screening, so low-risk women are recommended to wait and high-risk women are screened, may improve the balance of benefits and harms, as mathematical models have shown [3].

The most recent recommendations of the Spanish Family and Community Medicine Society (SemFYC) state that the primary care physicians should provide objective and proven information, motivating women to make an informed decision about their participation in the screening program, and also should collaborate in the identification of women at high risk due to a family or personal history of breast cancer [21]. Therefore, studies exploring attitudes, experiences and opinions of healthcare professionals that may play a prominent role in implementing risk-based screening programs in our setting are needed.

The objective of the study was to explore the barriers and facilitators of implementing a risk-based breast cancer screening program from the point of view of health professionals, in the context of the SpNHS. The study is part of the DECIDO project, which aims to assess the acceptability and feasibility of offering personalized breast cancer screening and its integration into clinical practice [11].

Methods

Design and methodologic perspective

A socio-constructivist qualitative study on the barriers and facilitators of personalized breast cancer screening, in the Catalan Health Service, was conducted. Using a descriptive and interpretive study we intended to find out the meaning and interpretation of these barriers and facilitators, based on the meanings and explanations that health professionals attribute to them, according to their context, experience and reflection [22].

Context and participants in the study

Field work was carried out in the cities of Lleida and Barcelona (Catalonia, Spain) between April and November 2019. The informants were health professionals (including health service providers, managers and administrative workers) from primary care, breast cancer screening programs, hospital breast units, epidemiology units, and clinical specialties such as oncology, radiation oncology, and diagnostic imaging.

Health professionals were selected according to a theoretical sampling strategy aimed at ensuring heterogeneity and capturing their potential discursive diversity [23]. The selection criteria were: work area in relation to breast cancer (early diagnosis, cancer treatment, and primary care), field of expertise (nurse, midwife, general practitioner, specialist or health manager), and geographical health area (Lleida, Bellvitge Hospital/Catalan Institute of Oncology, Parc de Salut Mar, and Vall d’Hebron Hospital).

The participant search was carried out by the research team. We contacted the heads of the health care services to inform them about the study and ask them to inform and request contact consent from health professionals working with them. Professionals interested in participating received information about the study, dates of the discussion groups, and were invited to send a reply on their decision to participate. The sample included 29 health professionals whose characteristics are described in Table 1.

Table 1. Characteristics of the study participants.

Discussion group (DG) Participants (P) Work area Health service area Professional profiles
DG1 P1 Primary Care Lleida Nurse
P2 Hospital Breast Unit Nurse
P3 Radiation Oncology Oncologist
P4 Primary Care Midwife
P5 Primary Care Physician
P6 Catalan Health Service Management
P7 Hospital Breast Unit Surgeon
P8 Hospital Breast Unit Psychologist
DG2 P1 Hospital Breast Unit Lleida Management
P2 Primary Care Nurse
P3 Breast Cancer Screening Program Management
P4 Radiation Oncology Nurse
P5 Primary Care Physician
P6 Hospital Breast Unit Nurse
P7 Radiation Oncology Nurse
DG3 P1 Hospital Breast Unit Barcelona Oncologist
P2 Diagnostic Imaging Service Radiologist
P3 Primary Care Physician
P4 Breast Cancer Screening Program Management
P5 Hospital Breast Unit Nurse
P6 Epidemiology and Evaluation Service Physician
P7 Primary Care Management
DG4 P1 Early Detection Unit Barcelona Radiologist
P2 Catalan Health Service Management
P3 Primary Care Physician
P4 Early Detection Unit Psychologist
P5 Breast Cancer Screening Program Physician
P6 Breast Cancer Screening Program Nurse
P7 Primary Care Management

Data collection

Discussion groups were held to collect the participants’ perspectives. A discussion group consists of a meeting of seven to ten people who have been selected based on specific profiles according to the research objectives, to comment and debate on a series of topics, induced by a moderator. It is intended to reproduce a micro-social situation in the image of what would be a macro-social situation, through the interaction of the different profiles, as an effective way of extracting experiences, reactions, emotions and ideas according to Patton et al. [24].

The intention was to build a debate based on an initial provocation (e.g. is it possible to implement a risk-based cancer screening program in the SpNHS?). The discussion group technique is less directive than the focus group, where the moderator has a guide of questions for organizing a discussion that are answered in a timely manner [25]. We intended to build a joint and open conversation from the discursive confrontation between the participants [23]. The discussion group provided a presentation and guided discussion about barriers and facilitators of implementing a risk-based breast cancer screening program from the perspective of health professionals. The list of open-ended questions, presented in S1 Table, was developed from a literature review. Each discussion group had a moderator with extensive experience in qualitative research (ACC or NCB) and an observer from the research team (MR or MC).

Four discussion groups were held, two in Lleida and two in Barcelona. Discussion groups were held at the Medical School of the University of Lleida and the headquarters of the Catalan Institute of Health in Barcelona. The team previously discussed and agreed on how to conduct the groups. Before starting the discussion group, the objectives of the study were presented and the concepts of personalized screening and shared decision-making were introduced. A brief summary of a proof of concept study about the feasibility and acceptability of risk-based screening, carried out by the DECIDO team, was presented [11]. Informed consent and permission for audio recording of the session were obtained. Then, the discussion was started by the open questions through the guided discussion (S1 Table). The duration of the discussion was approximately 90 minutes. At the end of the group discussion ACC and NCB took notes. The sessions were audiotaped and transcribed verbatim by two transcriptionists, not members of the study team, and later reviewed by ACC and NCB. The research team decided to end the data collection when the information obtained was considered sufficient to answer the research questions [26]. Transcripts of discussion groups were not returned to the participants for comments.

Data analysis and interpretation

The textual corpus made up of the discussion group transcripts was analyzed by two researchers who performed a descriptive-interpretive thematic analysis [27]. The entire research team participated in a session to interpret the results.

The transcript analysis consisted of a) reading and rereading the transcripts; b) reviewing the field work notes and writing the first intuitions and pre-analytic thoughts; c) coding texts and extracting categories in a mixed way (inductive and deductive) considering the objectives of the study and Légaré’s taxonomy that categorizes barriers and facilitators as knowledge, attitudes and behaviors [28]; d) reconstructing the categories by performing a work of contrast with the texts and between the texts, concept maps and analysis of co-occurrences between the discursive profiles and the barriers and facilitators identified in the analysis, in order to achieve an explanatory framework of the meanings according to the different discourses. The analysis was carried out with the support of the Atlas-ti version 8.4 software [29].

Quality and rigor

To ensure the validity of the study, different strategies were taken into account: discussion of the suitability of the strategy to generate information, theoretical sampling to ensure discursive variability, conducting four discussion groups to reach information saturation, and triangulation in the analysis and discussion of the results by the entire research team [30].

The participation of the entire research team fostered reflexivity throughout the development of the study, by discussing prior knowledge and experiences and explicitly describing preconceptions that were considered in both the design and interpretation of the results [23].

Ethical aspects

The Drug Research Ethics Committee of the University Hospital Arnau de Vilanova at Lleida approved the study. All the informants, after having been informed of the objective of the study and the involved institutions, participated voluntarily. The sessions were recorded guaranteeing the anonymity and confidentiality of the data. Thus, the identities of the participants and the references that could identify them were anonymized.

Results

Fig 1 summarizes the visions of healthcare professionals on the implementation of risk-based screening for breast cancer. Barriers and facilitators have been grouped in four categories, related to 1) women; 2) health professionals; 3) the risk-based screening program; and 4) the health system. Some organizational proposals about how to implement a risk-based program are listed at the bottom of Fig 1.

Fig 1. Visions of healthcare professionals on the implementation of risk-based screening for breast cancer.

Fig 1

Barriers and facilitators, related to women, for participating in personalized risk-based breast cancer screening

According to the informants perspective, the main barrier for women to participating in risk-based screening would be resistance to having fewer mammograms, for women at low-risk (Table 2). More than 30 years of promotional efforts to encourage participation in screening programs and intense media coverage of breast cancer have raised awareness of the disease. This can make it difficult to understand that a reduction in the number of mammograms can be beneficial, which may cause some women to reject the personalized screening recommendations and opt for using the private health system to ensure having annual or biennial mammographic exams.

Table 2. Selected quotes from health professionals’ discussion groups on barriers and facilitators for women regarding participation in risk-based screening.

Barriers: Resistance to change
The barriers are that a woman believes that a mammogram should be done every two years, or her private gynecologist has recommended she have a mammogram, and what she does is either go to the private gynecologist or the screening program. This woman, no matter how much you tell her it should be every three years because her risk is low […] (DG2P3)
Barriers: Rejecting the personalized screening recommendations
But, on the other hand, those who are used to biennial screening from the age of 50 onwards are now being told "well no, since your risk is low, in your case it will be every three years". How will this woman accept this? (DG1P4)
A barrier: to be told "you have to have a mammogram every three years" and then the GP tells you "if you who have private insurance, do it at the clinic" (DG2P5)
Facilitator: benefits of a risk-based program for young women
[…] But there is increasing demand from young women. They don’t know if they are at risk or not, if there is a family history then obviously look, look to the private system or primary care or whatever. (DG1P2)
I think it is good that a part of the population that now is not covered, ages 40 to 49, will have one mammogram every three or two or one years. I think that’s a facilitator (DG4P5)
Facilitator: proximity and trusting relationships with women
[…] Fortunately women have a good relationship with nurses and doctors, especially primary care or specialists and women kind of do what they tell them to do, right? […] (DG1P6)
Yes, yes, that would be a facilitator, every primary care doctor has their patients and can inform them about this program. (DG2P1)
Facilitator: growing interest and proactivity of women in their health care
And I think that women, who are already very proactive towards their health, if this decision can be made in an informed way, deciding for or deciding against, we will make the whole system more efficient. (DG3P1)
[…] And women have become empowered in breast cancer screening, in prevention because we know that if we detect it, we have better survival. And there are women in their 40s who come to ask us … This is why screening is so successful too. (DG1P3)
Facilitator: intensive media attention to breast cancer
Breast cancer now has become visible, on a social level, on a communication level, there is a lot of talk, a lot of famous people have said they have breast cancer, breast cancer is no longer a taboo […](DG1P3)

Facilitators that could reduce the impact of this barrier focus on the benefits of a risk-based program compared to “one size fits all.” A risk-based program would entail a) an initial risk assessment and a potential start of screening at a younger age, something that is not possible now, within the public health system, but many women would like, and b) more frequent exams and preventive measures for high-risk women. The participants expressed the need to inform women adequately in order to increase acceptance and participation. They also considered a facilitator the proximity and the relationship of trust that women have with their primary care professionals (PCP). An active role for PCPs could involve informing and inviting women to participate in the program. Participants also mentioned the growing interest and proactivity of women in decision-making related to their health, which may be a consequence of the strong diffusion of breast cancer burden through mass media. This has raised awareness among women and has increased their interest in early detection of the disease.

Barriers and facilitators associated with health professionals, for being involved in personalized risk-based breast cancer screening

With regard to barriers, the informants mentioned that even though there is evidence in favor of risk-based screening, there would be resistance to shifting from a model that has been in use for more than 30 years to a new one that requires significant changes in current practice and policy (Table 3).

Table 3. Selected quotes from health professionals’ discussion groups on barriers and facilitators for health professionals related to participating in risk-based screening.

Barrier: resistance to change
Of course, for example, from primary care what I see are the barriers set up by the professionals themselves. As a woman, I am more aware, but my colleague who is 50 years old perhaps is more aware of other aspects and not so much that. The barriers of the professionals themselves, one’s own resistances. That’s hard to work with. (DG2P5)
[…] cultural change within primary care physicians will be complicated. I don’t know, I mean, I’m optimistic from the study point of view, of people participating eagerly. But I don’t see this as an easy change! […] There are family doctors who do not want to get into this game because they do not want more work (DG3P7)
Barrier: difficulties in risk communication
Now please change this message, this conversation to Urdu. Thirty five percent of the migrant population in our center [speak Urdu]. It is very complicated. (DG4P7)
The issue is how society perceives these risks and how they are communicated! And obviously, it is true that here it is necessary to incorporate somebody with the ability to communicate risk, right? And knowing how to communicate positively and negatively, using the right words […] (GD3P1)
Barrier: professionals do not have training in risk communication and shared decision-making
[…] the issue of shared decisions, I think it’s an issue that will prevail, and therefore not just with this, but with everything! However, we the professionals are not sufficiently trained, maybe because […] or we do not have instruments or we do not have time or we still have to develop it more. (DG1P6)
Barrier: differing views on breast cancer screening recommendations
[…] we all know that screening has to be done every two years and that is what all doctors have to recommend to the patient. And there are doctors who say, "I would do it every year." In other words, it is not clear that all professionals agree, and breast cancer screening has been going on for more than 20 years! (DG1P1)
We may find that we tell a woman that she has a risk level that requires a mammogram every 3 years and another professional comes and says: “no, no, I would do it every year”. We are going to find that, for sure! (DG1P3)
[…] we run into a wall, if I go to the gynecologist and as they tell me “since you have a mother who had a breast neoplasm, you should have had at least one mammogram before 50, at least one”. I was 47 and I said yes. But that’s not it, is it? Messages can’t be like that. (DG4P7)
Facilitators: training of health professionals
Because, of course, they need specific training. Either give them a series of very clear items, and say you have to look at this, this and this […] (DG1P7)
Facilitators: levels of care coordination
[…] I believe that a risk-based program could never be done without the participation of all the people involved and a good information system behind it and good planning and estimation of needs, techniques, professionals […] (DG3P4)
Unify criteria. Please unify criteria, because the clinical guides say one thing, European urology says another, Catalan urology says another and Americans are saying another. Then, I am very sorry but I think it is one of the hardest battles. (DG4 P7)
Facilitators: receiving feedback and information on the program outcomes
Maybe it would also be good to see the result of all the work they have done, makes it more motivating to the professional, “well I have dedicated many hours to it, but I see the result”. This is important. (DG2P2)
And then there’s something super important, which has worked very well for us in colon screening, aside from training, it’s the feedback of the work done. If you give feedback to people, of the 400 women you have, in your clinic, who are 40 to 70 years old, these have done genomics and those have been diagnosed, this is not a lot of work for the professional, it doesn’t cost him anything, what costs is "do this" and you don’t give any feedback. (DG2P3)
Facilitators: lessons and experiences from other screening programs
In the colorectal screening we have worked very well because of the proximity of the patient to the healthcare professional […] And people say, "I have a health problem, I go to Dr. X, who is my doctor". (DG2P3)
[…] The "Cervix" went from [recommending] annual cytology to recommending every three years and there was quite a significant resistance from the population. It is a matter of informing well, explaining well […] (DG3P4)

Professionals were aware of the difficulty involved in communicating risk to women or developing shared decision-making so that women could decide whether or not to participate in screening. Thus, professionals of diverse profiles stated that, despite the fact that the estimated breast cancer risk can be considered an objective measurement, there are multiple aspects that a woman will consider, such as individual experiences and their environment. Participants called attention to the fact that most professionals do not have training in these subjects, turning this circumstance into a barrier.

Another barrier raised by the informants is the differing views on breast cancer screening recommendations among health professionals, which could also be the case if personalized screening was implemented. That would result in women not being offered the established recommendations and could cause confusion.

Participants raised some facilitators to mitigate the impact of the previously identified barriers. Among them, provision of systematic training over time to professionals involved in the program, especially those working in primary care. They also highlighted the importance of coordination of the different levels of care (primary care, current screening program, hospital services) and receiving feedback and information on the program outcomes. An information system shared by all the actors and an adequate allocation of human and economic resources were also considered important facilitators. Finally, the informants suggested building on the learnings and experiences of other existing screening programs, such as cervical or colon cancer, in which PCP or even pharmacists have participated.

Barriers and facilitators related to implementing a risk-based screening program

The informants considered the uncertainty related to the lack of conclusive evidence on the effectiveness of risk-based screening and insufficient accuracy of risk measures to be an important barrier (Table 4). Some participants emphasized that more research is needed before implementing risk-based screening. This barrier may contribute to resistance to change, and possibly both barriers feedback mutually to one another. A second barrier, signaled mostly by PCP, arose in relation to the hypothetical scenario that the program burden fell mainly on them. The informants, in general, agreed that primary care should be the gateway to the screening program and also the setting where risk is communicated and recommendations are made. However, PCP expressed concern and some even rejection, due to lack of time and job instability, unless relevant organizational changes were made. Finally, the participants noted the high costs of measuring risks for a large number of women in the initial phase of program implementation.

Table 4. Selected quotes from health professionals’ discussion groups on barriers and facilitators related to implementing a risk-based screening program.

Barrier: lack of conclusive evidence on the effectiveness of risk-based screening
[…] In order to introduce screening at the population level, a series of randomized clinical trials were carried out, it had to be shown over and over again that mammography is effective. To introduce personalized screening we are also going to need to provide convincing scientific evidence. And currently, what is the strong evidence to make a strong recommendation in favor of personalized screening over standard screening? Or instead of opportunistic screening? Or instead of not screening? At the moment I think, as far as I know, that the studies are underway, but there are no results. So, at this moment, it would be a barrier for me if I wanted to convince the people that I have around and they tell me: "hey, I already have a lot to do, why are you asking me to change?" (DG3P6)
Barrier: program burden may fall on primary care
One thing is the colon screening where you collect the sample and the other thing is the genomic test. The genomic test cannot be performed at home by the user, so they need assistance. Overloading primary care with more, there are 50,000 women and I don’t know what percentage will decide to not participate, but if we have 20% who will say no, we will have 40,000. (DG2P3)
[…] is a burden for primary care, probably unbearable from the current situation … If you are the primary care physician and you have to invite women, you need time or infrastructure … I understand […] (DG4P5)
Barrier: lack of time and job instability of primary care professionals
And, I’m talking from primary care … There’s a lot of nursing rotation …, monthly contracts and such, and now I’m going into policy a little bit. So what then? […] I cover several consultations … And our nurses are changing practically every month. (GD1P1)
[…] First, all these doctors have to be trained, and that’s not easy. I say this because I’ve tried it several times with breast topics and I haven’t quite gotten it, […]. And then there’s medical staff rotations, meaning you have the trained medical staff and over the holidays there are staff changes … (DGP2P1)
And it is also the lack of time, in primary care, what I see as the biggest problem, personally of course, is time. (DG2P2)
Barrier: high costs of measuring risks
The problem is that all, all women from the age of 40 onwards have to have a mammogram, the clinical history, the genomic study, plus the visit of the doctor or nurse who has to explain all these risks to you, economically I do not know if the health system can currently assume this for all women of 40 years of age. (DG1P3)
[…] There would also be a resource that has not been considered which is the laboratory. There will be hundreds of SNPs to evaluate. (DG3P4)
Facilitator: increased accuracy in risk quantification
… the more the screening program is adapted to the probability of having cancer, the better it works. Therefore, you would remove women with very low probability and improve the precision for women with very high probability. I think conceptually, yes. (DG3P4)
What happens is that perhaps this more accurate estimate of risk is not all of a sudden. I think doing this would be a huge step in the accuracy of risk, which is not being done anywhere in the world. (DG4P4)
Facilitator: higher efficiency of risk-based screening
I think screening with mammography has reached its ceiling […] And there is a need for change […] it will no longer be considered beneficial because […] it is already being demonstrated […]. In addition, we have tools that allow us to better estimate risk. […] And you give value to the test and also to the risk estimate. This is very important for adherence! (DG3P1)
[…] 30% of breast cancers we treat in Lleida are in women less than 50 years old and 30% are over 70. Therefore, we have 60% of the population outside the screening program. The impression we have is that there are patients, people, women, who do not need to do a biennial screening program and instead, there are women who are outside the age range who will surely need it. And I think it’s a very, very interesting program. (DG2P1)

On facilitators, informants stated the above mentioned benefits plus increasing accuracy in risk quantification, implementing shared decision-making, and allocating more screening resources to the high-risk group for a higher efficiency. These seemed like strong arguments for informants to justify the need to move toward risk-based screening.

Health systems barriers and facilitators, for implementing personalized risk-based breast cancer screening

Since the potential implementation of risk-based breast cancer screening will require extensive changes in current practice, the informants expressed that the change would not be possible without the commitment of health policy makers and an adequate budget allocation for program implementation and maintenance (Table 5). In fact, the extra amount of financial and human resources for the implementation of the program is an economic barrier. Another barrier mentioned was the set of limitations of the current information system regarding the real-time integration of screening data and clinical records, as well as the access of all health professionals involved in the screening program.

Table 5. Selected quotes from health professionals’ discussion groups on health system barriers and facilitators.

Barriers: commitment of health policy makers
[…] the problem comes from bureaucracies and administrations (DG2P3)
[…] another barrier for me, and more in what we are discussing, is the decision of the Department of Health […] (DG3P7)
Barriers: adequate budget allocation
Well, I think that’s the first requirement, right? You cannot initiate a policy without a budget. It is important. (DG3P2)
[…] The problem I see most as the main barrier is: who pays for these mammograms? It’s basically … Who pays for everything? (DG4P3)
Barrier: limitations of the current information system
Yes, I think the data system we have is a barrier. There are people who don’t get the invitation … People who come to you for a consultation and say “I have not received anything about the mammography” or “I have not” and you try to redirect them to the programs, but we see this with a certain … frequency, because of database problems. (DG4P7)
[…] the whole subject of information technology in our environment is very slow, but not impossible. Different hospitals have different information systems. I think it’s good to be determined and optimistic but it’s complicated (DG3P7)
Facilitators: commitment of health policy makers
If there is money and there is a good information system, I think the population benefit will be impressive. (DG2P3)
Facilitators: friendly and comprehensive information system
There is a basic issue […] a very well-designed information system would be needed. With a good computer program that makes a classification of the risk groups, I think the assessment is not complicated and can be done. (DG2P1)
[…] in the same way that you have a tab that says “clinical course", "documentation" or “diagnostic tests", I think that for any woman over 40 years of age a new tab should appear with " breast cancer risk" […] And, there, the information could be updated, each time there is a change. (DG3P1)

Considering the identified barriers, the facilitators that would reduce their impact are, on the one hand, the commitment of health policy makers to implement the program with its corresponding budget and human resources allocation, and on the other hand, a friendly and comprehensive information system that connects the different actors involved and facilitates communication between them.

Organizational proposals for the implementation of a personalized breast cancer screening program

The open questions were: How should the personalized screening program be organized? Who would do the different functions? There was no consensus on how to organize a personalized screening program and there was controversy on the role of professionals that work at the current screening programs and in primary care. However, the section has limitations as it was not deepened enough due to lack of time. The moderators were strict on the planned time in order to prevent the informants fatigue.

First, the informants discussed who should and how to make the first contact for informing and inviting women to the program (Table 6). They proposed that women be invited by primary care physicians and nurses in clinical encounters or by a breast cancer screening program by mail or phone. They also suggested that more time and adapted decision aids would be necessary for women with a low educational level and/or language barriers.

Table 6. Selected quotes from health professionals’ discussion groups on organizational proposals for a risk-based screening program.

Invitation to women
[…] it is important that we think that in primary care there are family doctors and nurses. […] So, I think that at the women’s first visit, women’s questions, mammogram referral, taking saliva samples, etc., initial explanation of the program and concepts of overdiagnosis and quaternary prevention, I think a nurse could do that perfectly. (DG4P3)
First, everyone has to be involved, all the actors, primary, specialized, and radiology also thinking in the same way, and then develop a software that maintains it … which would pose two things: one, how do you approach the population. That is, how do you call them, if you wait for them to come or you call them, and once they have come there is also something that has not been considered; the family doctor sees it, but someone has to organize the agendas, considering that you have this entire population, where one needs an annual mammogram, another every three years, another every two […] In other words, technical offices will be necessary, but we can be an actor who organizes it so that it is primary care who makes the contact, which would be an ideal solution, perfectly trained nurses could do that, and people who simply organize. And don’t worry, I would already be behind for […] (DG3P4)
Risk measurement and risk-based recommendations
I imagine it as inviting a patient to a first visit … near radiology, where someone does the saliva extraction to assess the SNPs, the first mammogram, the radiologists classify the density in the same way, so that the measurement is also accurate, that everything goes into a database where SNPs, the density and the demographic questionnaire are added, and the risk assessment of a first contact with a professional, be it a nurse or a family doctor, that explains it to her. (DG3P4)
[…] and once the risk results arrive, with a leaflet or decision aid, if it’s negative and very low risk, a nurse could do it. If … a little more risk, maybe then it’s worth it for the doctor to explain it, right? (DG4P3)
Who and how to do the follow-up?
[…] once there is an estimated risk it is obvious. I mean, if a woman has to do it every year, she has to do it every year. And the one every three years, too. Then the thing would be that the technical office, at this time, the screening program would act to schedule women and mammograms, because the reading task would already be done by the trained radiologists. (DG2P3)
I understand that one thing is the admission into the program and identifying women and stratifying them by risk, I understand that this is a starting point, but then all the invitations of the following successive exams every year, every two years, every three or every five, I understand that another entity does it or it is the same primary care that is already inside the wheel. (DG4P3)
Need of educational programs targeted to health professionals and women
Let’s make an ad on TV and in many newspaper articles. People are already beginning to understand. (DG4P3)
Informative materials should be adapted, there should be materials translated into other languages and culturally and educationally adapted, the explanation for people with a lower level of education. (DG2P2)

Second, they debated risk measurement and risk-based screening recommendations. The informants emphasized the importance of communicating individual risk in plain language, to improve understanding and decision-making. They proposed that primary care physicians and nurses communicate risk and make screening recommendations, given that most women have a trusting relationship with them. High risk should be communicated by physicians whereas moderate or low risk could be communicated by nurses. In fact, there was a general consensus on the role that nurses could play in personalized risk-based screening.

Third, the discussion dealt with who and how to perform the individual follow-up. Informants considered that, with a good IT system, it could be done either by the screening program or PCP. If primary care managed the follow-up, additional resources for this health level would be needed. For high-risk women, breast specialists should inform and follow them up.

Finally, the participants indicated the need for educational programs targeted to health professionals and women, including mass media campaigns for large audiences. They expressed their confidence in these interventions to reduce resistance to change and facilitate the acceptance and participation of women.

Discussion

This study explored, using a qualitative approach, the barriers and facilitators to the implementation of a risk-based breast cancer screening program as well as some organizational proposals for its implementation, from the point of view of a diverse group of healthcare professionals working in the SpNHS.

Barriers and facilitators related to women

The participants expressed concern about a reduction in the number of screening mammograms for low-risk women, a finding consistent with other studies. In the UK, Meisel et al. [31] explored attitudes towards modifying frequency of mammography screening based on genetic risk. They found that although 65.5% of the women supported the idea of varying the screening frequency, only 58.8% were willing to reduce mammographic exams if they were found at lower risk. Instead, 85.4% were willing to increase the frequency if at higher risk. A study of European women’s perceptions found that more intensive screening for women with above average risk was generally welcomed, but screening recommendations for the other risk categories were met with skepticism [32]. Another study, which assigned participants to one of four hypothetical breast cancer risk scenarios (low, average, moderate, or high), with subsequent screening and prevention recommendations, found again that women’s level of acceptance depended on their assigned risk category [33]. Only 13.1% of the women assigned to the low risk scenario found a 4-year screening interval acceptable, with 27.4% of these women opting for supplemental mammography screening outside of the national screening program.

Several authors have discussed the reasons for this barrier. In a qualitative study with North American women [34], personal acceptance of risk-based screening was mixed. While some believed that risk-based screening could reduce harms, others thought screening less often might result in missing a dangerous diagnosis, and many expressed concerns about the feasibility of risk-based screening and questioned whether breast cancer risk estimates could be accurate—either because women did not remember risk factors or were confused about how risk would be calculated. Some women also suspected that risk-based screening was motivated by a desire to save money rather than reduce harms. Dutch women described the role of perceived risk in the acceptability of personalized exams. They believe that if their estimated risk does not correspond to their perceived risk, they will be less likely to accept the screening advice [32].

In the UK, McWilliams et al. [35] explored healthcare policy decision-making stakeholders’ views on a low-risk breast screening pathway. Participants identified individual beliefs about risk and knowledge of breast cancer and screening as key factors that impact women’s responses to low-risk stratification. Among uncertainties that need to be resolved before implementation, they signaled accurate identification of low-risk women, gaining women’s acceptance, and having evidence of lack of harm. In a study with professionals, Rainey et al. [36] suggested that women will question their personal risk information and their assigned pathway of care (screening frequency or biomedical prevention) and they expected an increase in opportunistic screening, particularly from women at low risk. As some authors suggest, there is a need for a) educating women on the benefits and harms of risk-based screening and prevention, to facilitate acceptability and informed decision-making [16], and b) developing effective communication materials to minimize resistance to screening reduction for those at lower risk [31]. A research synthesis on factors associated with the acceptability of human papillomavirus HPV testing for cervical cancer found that strategies that increase women’s knowledge and efforts to increase health care providers’ awareness might also increase acceptability of wider screening intervals [37].

Unlike other studies [16, 38, 39], participants in our study did not consider the potential discrimination that women may suffer from the use of their individual risk data for employment issues or health insurance discrimination to be a barrier. The universal health coverage of the SpNHS with free access to health care may explain this result.

Our study participants identified several facilitators, related to women, for participating in a risk-based screening program. First, and consistent with Puzhko et al. [14], they considered that a risk-based screening program is beneficial for women, especially for those at a higher-than-population average level of risk and for those who have objective (e.g. family history) or subjective reasons to be concerned. Thus, for some women, knowing the risk would be reassuring and would reduce anxiety, which would facilitate their participation in the program and in shared decision-making. This, in turn, could reduce the inappropriate use of opportunistic screening [14] and increase the attendance at subsequent screening exams [40]. However, Puzhko et al. emphasized that women may not truly benefit from risk-based screening unless their health professionals understand the risks and benefits of screening and can interpret the results adequately [14]. Second, several studies suggest that a healthcare professional (i.e. primary care physician or nurse) should be involved in the invitation, risk stratification, risk communication and follow-up of women in a risk-based screening program [41]. As participants in our study mentioned, a relationship of trust with the health professional [14], as well as relying on the experience of risk communication acquired from other health conditions in preventive medicine [42], would facilitate a personalized approach [43]. Third, the increasing participation of women in decisions that affect their health represents an incentive to participate in a personalized screening program. Our results agree with those of other studies reporting risk knowledge as an opportunity to have a proactive attitude [32], by being aware of the impact that breast cancer could have on women’s lives [44]. Likewise, health professionals value the proactive approach to shared decision-making, as women can take control of some of their risk factors, take steps to reduce them and try to avoid breast cancer, all findings that are in line with women finding risk based screening acceptable [36].

Barriers and facilitators associated with health professionals

Our results showed greater knowledge and a more positive attitude on the part of professionals towards personalized screening when compared to a previous study conducted in 2016 [45]. In line with this view, Puzhko et al. [14] reported that health professionals acknowledged the substantial benefits of the risk-based program. However, our discussion groups, as others have reported, expressed concern about the critical view of health professionals as a result of the uncertainty in the evidence on the safety and cost-effectiveness of the risk-based approach [35], and the resistance to change of professionals, reluctant to modify their established routine.

According to our study, training is essential for successfully implementing a program. Our results are consistent with other studies that identified professionals’ concerns about lack of competence to communicate risk and subsequent screening recommendations effectively [1416]. These authors suggested implementing educational programs that address these knowledge deficits, for each woman and risk category. Our study participants discussed how to implement training in the primary care setting, taking into account the diversity of settings (urban versus rural) and the mobility of health professionals. They also proposed strategies addressed at improving their training.

The increase in complexity of risk-based screening will require collaboration at multiple levels of care. Although Rainey et al. [16] suggested that the countries that already have a population-based screening program may experience fewer difficulties implementing risk-based screening, in our country it will be necessary to improve collaboration between primary care, population-based screening programs, and also specialized care for high-risk women.

Moreover, all discussion groups considered it essential that Health Authorities incorporate the personalized screening program into a health policy goal with adequate allocation of human and economic resources. Only then, dissemination of the personalized program, women’s risk assessment, risk communication and levels of care coordination can be guaranteed. Without a health policy commitment and budget allocation, professionals perceive that there will be resistance to change. These results are concordant with previous studies. Whereas Esquivel-Sada et al. [15] pointed out the lack of confidence of professionals in the public health system to provide an adequate allocation of human and economic resources, McWilliams et al. [35] stated that risk stratification is potentially profitable and consequently, further study of the cost-effectiveness around personalized risk-based programs will be necessary.

Barriers and facilitators related to implementing a risk-based screening program

As a barrier, participants mentioned the uncertainty around the effectiveness of risk-based screening. Their doubts relied on the lack of evidence of benefits from a risk-based model compared to the current age-based program. To advance in this area, the European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) network [46] brings together several international research consortia, from 19 countries, working on different aspects of personalized early detection and prevention of breast cancer. The network highlights how risk stratification has improved with the use of comprehensive models incorporating genetic and epidemiological risk factors and mammographic breast density, which have shown an excellent calibration for the European, Hispanic and African-American population [7]. Recent studies report that PRS models derived from women with European ancestry for breast cancer risk generalized well for women with European and Latina ancestries and to a lesser degree to women with African ancestry where further studies with larger sample size are needed [47, 48]. Although research is still ongoing to assess the clinical utility of PRS for population screening programs, Yanes et al. point out that polygenic testing is already being implemented in specialist familial cancer clinics to provide additional information for women with family history and uninformative genetic test results [7].

On the one hand, despite the doubts expressed by professionals as a result of the lack of evidence of the effectiveness of risk-based screening, they recognized that it would provide greater accuracy in measuring individual risk. Thus, health professionals seemed to have a good predisposition towards risk-based screening. However, as Petrova et al. [17] propose it is essential that they know the results of the research and understand the statistics of early detection in order to avoid misleading and potentially harmful recommendations. Additionally, the general population should be exposed to media campaigns that inform them about the pros and cons of a risk-based program [42].

On the other hand, the barriers that most concern our professionals come from the organizational system, in particular the fear of an increase in the workload for PCP and the lack of economic resources. These impressions are based on the fact that the implementation of the personalized program involves a more complex organization and more agents involved [16] such as patients, providers, facilities, health care systems, and regional and national policy-making organizations [43, 49]. In addition, our study participants assume that there is an increase in costs derived from the genetic information in risk measurement and the time spent by professionals in communicating risk and shared decision-making. These costs would be largely offset by the increased effectiveness and efficiency of risk-based screening [3, 9, 5053], as well as by greater well-being provided by fluid communication between women and professionals regarding risk monitoring [18, 54]. A reduction of professionals’ workloads could be achieved if women participated more actively (e.g. self-collection of saliva samples and self-completion of data) under a nurses’ supervision [43, 55]. In this line, our health professionals considered that their involvement would be facilitated if the current screening program were restructured, incorporating an adequate relationship with the health system and coordination with other levels of care.

Health systems barriers and facilitators, for implementing personalized risk-based breast cancer screening

Implementing personalized screening will require substantial organizational changes to the current healthcare model [16, 50]. Despite the need for health interventions to evolve when new evidence appears, substantial efforts will be required to abandon a screening program in use for more than 30 years and to introduce a new one that still presents uncertainties. Health professionals are used to changes in clinical protocols as new studies support them, but they are reluctant to face organizational changes whose dimension and effects they do not control. Rainey et al. suggest that countries that already have an organized, population-based screening program in place may experience fewer difficulties implementing a risk-based screening program [16], and professionals in our study consider that the experience with other risk-based interventions would reduce reluctance to change. Likewise, Bellhouse et al. [41] conclude that the integration of risk assessment and management tools into practice software or access to web-based applications would facilitate this change, as happened for cardiovascular risk assessment and management.

Professionals participating in our study indicated that risk-based screening would only be possible if the current IT tools were updated. Similarly, Puzhko et al. [14] emphasize the importance of integrating the risk calculator into the electronic medical record and Yi et al. [18] emphasize the need for developing electronic decision aids to enhance risk communication. Likewise, information systems must integrate electronic medical record and screening information in an easy and accessible way for all stakeholders. This would facilitate monitoring the risk of breast cancer overtime, accounting for potential changes in risk factors [16, 18].

Decision aids are needed to allow participatory health models such as shared decision-making [14]. Decision aids allow communication of the risks and benefits of screening in a balanced way, and work together to reach a decision about adherence to the program, based on clinical evidence and the patient’s informed preferences [16, 54]. Studies show that women participating in shared decision-making have a greater commitment to health decisions, since they feel more responsible for their actions. This would allow women to reduce barriers related to anxiety, decisional conflict, and to prefer more beneficial and less invasive options [28, 56, 57], that is, to better manage the expectations of a risk-based program [16]. We included shared decision-making in our discussion group guide as an innovative strategy in screening. We were interested in knowing the views of health professionals about their implementation, considering that some barriers that have been reported in the literature have their origin in professionals’ resistance to change [58].

Our study participants argued that the costs of updating the IT system and implementing shared decision-making, together with the aforementioned costs of genetic determinations and human resources for risk communication, will lead to budget increases. However, there is evidence in favor of risk-based screening being more efficient [3, 5153], providing more resources to women at higher risk and fewer to those at lower risk. Harkness et al. [52] showed that compared to age-based screening, not offering screening to women in the lowest tertile of risk could improve effectiveness, cost-effectiveness, and decrease overdiagnosis, whilst resulting in a small excess of breast cancer deaths. However, Vilaprinyo et al. [3], in a modeling study, found that risk-based screening could reduce breast cancer mortality. Therefore, an economic evaluation of risk-based screening at the local level should be performed.

Given that both structural and organizational changes as well as an increase in economic resources will be required, the implementation of risk-based screening cannot be carried out without strong conviction from policy makers, health care providers, and regional and national authorities, to develop patient-centered medicine [49, 59, 60]. Therefore, declaration of intent is not enough, it is necessary to develop specific strategies for the application of risk-based screening [59, 60].

Finally, the evidence also supports the consensus reached in our discussion groups; primary care should be the gateway to the new program [14, 16, 41, 50]. However, among the professionals in our study, there was no agreement on which professionals should be in charge of risk communication and risk counseling, although nurses and family doctors were the most cited. In an European study [59], Dutch and Swedish women agreed that below average and average risk results can be relayed in a letter, while above average risk feedback should be done through a telephone or face-to-face consultation with a family doctor or a specialized nurse, with expert knowledge in the field. British women at below average to average risk were also satisfied receiving information on their risk in a letter, but women at moderate or high risk recommended the development of special women’s clinics operated by specialized nurses, radiographers, radiologists, and gynecologists, integrating breast and cervical cancer screening. British women also signaled a need to educate professionals on all aspects of risk-based screening and prevention in order to prevent the provision of conflicting information, and also a need for pathways and protocols to standardize interaction between primary and secondary care providers to avoid individual variation [59]. In line with this result, Culver et al. [61] and Bellhouse et al. [41] found that primary care physicians require more training in risk assessment and risk communication before facing complex scenarios in high-risk women. This evidence preserves some elements of the current screening program, such as the delivery of information by letter and telephone follow-up. However major changes are needed in several elements, such as information systems or risk communication protocols, for the implementation of a personalized risk-based screening.

Strengths and limitations

To our knowledge, this is the first study in Spain that intended to obtain a description of barriers and facilitators as well as a global assessment of the difficulties in implementing a risk-based breast cancer screening program, all from the perspective and experiences of health professionals working in the NHS. The views of the different stakeholders involved in the screening, diagnosis and treatment of breast cancer have provided valuable information to pave the way for the implementation of personalized breast cancer screening.

Our study has some limitations. First, collecting data from discussion groups may have produced a social desirability bias in the discourse [62]. However, the triangulation of information through observations and data with the participation of different professionals, in addition to contributing to a better understanding of the phenomenon, relativized this possible bias by corroborating the convergences, divergences and complementarity of data obtained in the discussion groups [63]. In addition, reflexivity was maintained during the research process with the participation of the entire research team and the use of information from field notes [64]. Second, the four discussion groups had a heterogenous profile that limited the saturation of specific perspectives or views. However, the research team considered that for most of the topics discussed the information obtained was sufficient to answer the research questions. Third, not all our findings may be generalizable to other health systems. Nonetheless, many of them may be transferable to health systems with population-based screening programs. Fourth, participants’ perspectives on perceived barriers and facilitators may have been influenced by the way the research team presented the most relevant changes in risk-based screening, compared to the current screening: risk measurement and communication and the corresponding screening recommendations.

Conclusions

Despite the barriers and limitations identified, study participants were supportive of the implementation of risk-based screening. They highlighted the benefits of risk-based screening, especially for women at high risk of breast cancer and those under 50 years of age. They stressed that allocating more resources to these women is not only beneficial for them, but also translates into a greater efficiency of the risk-based program compared to the current one.

However, the implementation of risk-based screening would pose a great challenge for the SpNHS due to organizational and administrative transformations, and also due to the need for commitment and political will. Other challenges come from the need for coordination between the different levels of care; improvements to information systems; education of health professionals on personalized screening, risk communication and shared decision-making; and dissemination of information through public campaigns, guaranteeing that it is accessible to the entire population. As facilitators of the implementation, the participants highlighted the experience of PCP in other screening programs; the relationship of trust and the closeness of these professionals with women; the awareness of women about breast cancer and early detection; and the increasingly proactive role of women in their health care.

More studies are needed that expand knowledge and understanding about the views of health professionals, health system administrators and those responsible for formulating public health policies, on the viability of risk-based screening for breast cancer and its future implementation; and also the acceptance of this strategy by women. Future studies should assess the efficiency and feasibility of implementing risk-based breast cancer screening in clinical practice in the SpNHS.

Supporting information

S1 Table. Discussion groups guide.

(DOCX)

Acknowledgments

We thank the health professionals who generously and actively participated in the discussion groups. We also thank JP Glutting for reviewing and editing the manuscript.

The DECIDO Group

Members of the DECIDO Study Group: Pau Balaguer-Llaquet; Iván-David Benítez; Alexandra Bertran; Àngels Cardona; Cristina Cazorla-Sánchez; Núria Codern; Inés Cruz-Esteve; Carles Forné-Izquierdo; Marta Hernández-Andreu; María José Hernández-Leal; Edelmir Iglesias; Gisela Galindo-Ortego; Celmira Laza-Vásquez; Montserrat Llorens-Gabandé; Montserrat Martínez-Alonso; Hèctor Perpiñán; Anna Pons-Rodríguez; Mercè Reñé-Reñé; Montserrat Rué; Isabel Sánchez-López; Jordi Vilaplana-Mayoral.

Data Availability

Data consists of recorded group discussions and the corresponding transcriptions. Languages used were Catalan and Spanish. Data cannot be shared publicly because we did not ask participants' consent to share the recorded materials. Data are available from the The Drug Research Ethics Committee of the University Hospital Arnau de Vilanova at Lleida (contact via e-mail ceim.lleida.ics@gencat.cat) for researchers who meet the criteria for access to confidential data.

Funding Statement

MR PI17/00834: Personalized breast cancer screening: assessment of its feasibility and acceptability in the National Health System. Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’ https://www.isciii.es MCL PI18/00773: Collaboration of healthcare professionals to include shared decision-making in the breast cancer screening program. Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’ https://www.isciii.es CLV Santander Program scholarship 2020: predoctoral fellow at the University of Lleida MJH-L: European Regional Development Fund (ERDF). European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 713679 from the Universitat Rovira i Virgili (URV). The funders did not participate in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;n/a. 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  • 2.Marmot MG, Altman DG, Cameron D, Dewar J, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: An independent review. Br J Cancer. 2013;108: 2205–2240. doi: 10.1038/bjc.2013.177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Vilaprinyo E, Forné C, Carles M, Sala M, Pla R, Castells X, et al. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One. 2014;9: e86858. doi: 10.1371/journal.pone.0086858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bitencourt AGV, Saccarelli CR, Kuhl C, Morris EA. Breast cancer screening in average-risk women: Towards personalized screening. Br J Radiol. 2019;92. doi: 10.1259/bjr.20190660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, et al. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016;159: 513–525. doi: 10.1007/s10549-016-3953-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Vachon CM, Scott CG, Tamimi RM, Thompson DJ, Fasching PA, Stone J, et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Res. 2019;21: 1–10. doi: 10.1186/s13058-018-1086-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yanes T, Young MA, Meiser B, James PA. Clinical applications of polygenic breast cancer risk: A critical review and perspectives of an emerging field. Breast Cancer Res. 2020;22: 1–10. doi: 10.1186/s13058-020-01260-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Evans DGR, Harkness EF, Brentnall AR, Veen EM van, Astley SM, Byers H, et al. Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Res Treat. 2019;176: 141–148. doi: 10.1007/s10549-019-05210-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Román M, Sala M, Domingo L, Posso M, Louro J, Castells X. Personalized breast cancer screening strategies: A systematic review and quality assessment. PloS One. 2019;14: e0226352. doi: 10.1371/journal.pone.0226352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.French DP, Astley S, Brentnall AR, Cuzick J, Dobrashian R, et al. What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer. 2020;20: 1–14. doi: 10.1186/s12885-020-07054-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Pons-Rodriguez A, Forné Izquierdo C, Vilaplana-Mayoral J, Cruz-Esteve I, Sánchez-López I, Reñé-Reñé M, et al. Feasibility and acceptability of personalised breast cancer screening (DECIDO study): Protocol of a single-arm proof-of-concept trial. BMJ Open. 2020;10. doi: 10.1136/bmjopen-2020-044597 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Coulter A, Jenkinson C. European patients’ views on the responsiveness of health systems and healthcare providers. Eur J Public Health. 2005;15: 355–360. doi: 10.1093/eurpub/cki004 [DOI] [PubMed] [Google Scholar]
  • 13.Elwyn G, Frosch D, Volandes AE, Edwards A, Montori VM. Investing in deliberation: A definition and classification of decision support interventions for people facing difficult health decisions. Med Decis Making. 2010;30: 701–11. doi: 10.1177/0272989X10386231 [DOI] [PubMed] [Google Scholar]
  • 14.Puzhko S, Gagnon J, Simard J, Knoppers BM, Siedlikowski S, Bartlett G. Health professionals’ perspectives on breast cancer risk stratification: Understanding evaluation of risk versus screening for disease. Public Health Rev. 2019;40: 1–19. doi: 10.1186/s40985-019-0112-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Esquivel-Sada D, Lévesque E, Hagan J, Knoppers BM, Simard J. Envisioning implementation of a personalized approach in breast cancer screening programs: Stakeholder perspectives. Healthcare Policy. 2019;15: 39–54. doi: 10.12927/hcpol.2019.26072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rainey L, Waal D van der, Jervaeus A, Wengström Y, Evans DG, Donnelly LS, et al. Are we ready for the challenge of implementing risk-based breast cancer screening and primary prevention? Breast. 2018;39: 24–32. doi: 10.1016/j.breast.2018.02.029 [DOI] [PubMed] [Google Scholar]
  • 17.Petrova D, Mas G, Navarrete G, Rodriguez TT, Ortiz PJ, Garcia-Retamero R. Cancer screening risk literacy of physicians in training: An experimental study. PLoS One. 2019;14: 1–17. doi: 10.1371/journal.pone.0218821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, et al. Barriers and facilitators to patient-provider communication when discussing breast cancer risk to aid in the development of decision support tools. American Medical Informatics Association, Annual Symposium proceedings AMIA Symposium. 2015;2015: 1352–1360. [PMC free article] [PubMed] [Google Scholar]
  • 19.Kukafka R, Fang J, Vanegas A, Silverman T, Crew KD. Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting. BMC Med Inform Decis Mak. 2018;18: 1–12. doi: 10.1186/s12911-017-0580-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, et al. Cancer screening in Spain. Ann Oncol. 2010;21: 43–51. doi: 10.1093/annonc/mdq085 [DOI] [PubMed] [Google Scholar]
  • 21.Marzo-Castillejo M, Vela-Vallespín C, Bellas-Beceiro B, Bartolomé-Moreno C, Ginés-Díaz Y, Melús-Palazón E. Grupos de Expertos de Cáncer del PAPPS. Recomendaciones de prevención del cáncer. Actualización PAPPS 2020. Aten Primaria. 2020;52: 44–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Denzin N, YS L. The SAGE handbook of qualitative research. Thousand Oaks: SAGE Publications, Inc; 2011. [Google Scholar]
  • 23.Zarco J, Ramasco M, Pedraz A, A P. Investigación cualitativa en salud (Cuadernos Metodológicos 58). Editorial CIS (Centro de Investigaciones Sociológicas); 2019.
  • 24.Patton MQ. Qualitative research and evaluation methods: Integrating theory and practice. Thousand Oaks: SAGE Publications, Inc; 2015. [Google Scholar]
  • 25.Krueger RA. Analyzing focus group interviews. Journal of Wound, Ostomy and Continence Nursing. 2006;33: 478–481. doi: 10.1097/00152192-200609000-00004 [DOI] [PubMed] [Google Scholar]
  • 26.Minayo M. Amostragem e saturação em pesquisa qualitativa: Consensos e controvérsias. Revista Pesquisa Qualitativa. 2017; 5: 1–12. [Google Scholar]
  • 27.Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3: 77–101. doi: 10.1191/1478088706qp063oa 32100154 [DOI] [Google Scholar]
  • 28.Légaré F, Ratté S, Gravel K, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: Update of a systematic review of health professionals’ perceptions. Patient Educ Couns. 2008;73: 526–535. doi: 10.1016/j.pec.2008.07.018 [DOI] [PubMed] [Google Scholar]
  • 29.ATLAS.ti. Qualitative data analysis, version 8.4 [Internet]. Berlin, Germany: ATLAS.ti Scientific Software Development GmbH; 2019. Available: https://atlasti.com/
  • 30.Calderón C. Assessing the quality of qualitative health research: Criteria, process and writing. Forum Qual Soc Res. 2009;10. doi: 10.17169/fqs-10.2.1294 [DOI] [Google Scholar]
  • 31.Meisel SF, Pashayan N, Rahman B, Side L, Fraser L, Gessler S, et al. Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast. 2015;24: 237–241. doi: 10.1016/j.breast.2015.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rainey L, Jervaeus A, Donnelly LS, Evans D, Hammarström M, Hall P, et al. Women’s perceptions of personalized risk-based breast cancer screening and prevention: An international focus group study. Psychooncology. 2019;28: 1056–1062. doi: 10.1002/pon.5051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rainey L, Van Der Waal D, Broeders MJM. Dutch women’s intended participation in a risk-based breast cancer screening and prevention programme: A survey study identifying preferences, facilitators and barriers. BMC Cancer. 2020;20: 1–14. doi: 10.1186/s12885-020-07464-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.He X, Schifferdecker KE, Ozanne EM, Tosteson ANA, Woloshin S, Schwartz LM. How do women view risk-based mammography screening? A qualitative study. J Gen Intern Med. 2018;33: 1905–1912. doi: 10.1007/s11606-018-4601-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.McWilliams L, Woof VG, Donnelly LS, Howell A, Evans DG, French DP. Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders’ views on a low-risk breast screening pathway. BMC Cancer. 2020;20: 1–11. doi: 10.1186/s12885-020-07158-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Rainey L, van der Waal D, Donnelly LS, Evans D, Wengström Y, Broeders M. Women’s decision-making regarding risk-stratified breast cancer screening and prevention from the perspective of international healthcare professionals. PLoS One. 2018;13: e0197772. doi: 10.1371/journal.pone.0197772 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tatar O, Thompson E, Naz A, Perez S, Shapiro GK, Wade K, et al. Factors associated with human papillomavirus (HPV) test acceptability in primary screening for cervical cancer: A mixed methods research synthesis. Prev Med. 2018;116: 40–50. doi: 10.1016/j.ypmed.2018.08.034 [DOI] [PubMed] [Google Scholar]
  • 38.Hall AE, Chowdhury S, Hallowell N, Pashayan N, Dent T, Pharoah P, et al. Implementing risk-stratified screening for common cancers: A review of potential ethical, legal and social issues. J Public Health. 2014;36: 285–291. doi: 10.1093/pubmed/fdt078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lévesque E, Kirby E, Bolt I, Knoppers BM, De Beaufort I, Pashayan N, et al. Ethical, legal, and regulatory issues for the implementation of omics-based risk prediction of women’s cancer: Points to consider. Public Health Genomics. 2019;21: 37–44. doi: 10.1159/000492663 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Evans DGR, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, et al. Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer. 2016;114: 1045–1052. doi: 10.1038/bjc.2016.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bellhouse S, Hawkes RE, Howell SJ, Gorman L, French DP. Breast cancer risk assessment and primary prevention advice in primary care: A systematic review of provider attitudes and routine behaviours. Cancers. 2021;13: 1–23. doi: 10.3390/cancers13164150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lévesque E, Hagan J, Knoppers BM, Simard J. Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. New Genet Soc. 2019;38: 38–59. doi: 10.1080/14636778.2018.1549477 [DOI] [Google Scholar]
  • 43.Silver E, Wenger N, Xie Z, Elashoff D, Lee K, Madlensky L, et al. Implementing a population-based breast cancer risk assessment program. Clin Breast Cancer. 2019;19: 246–253.e2. doi: 10.1016/j.clbc.2019.02.009 [DOI] [PubMed] [Google Scholar]
  • 44.Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. The introduction of risk stratified screening into the NHS breast screening Programme: Views from British-Pakistani women. BMC Cancer. 2020;20: 1–9. doi: 10.1186/s12885-020-06959-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Toledo-Chávarri A, Rué M, Codern-Bové N, Carles-Lavila M, Perestelo-Pérez L, Pérez-Lacasta M, et al. A qualitative study on a decision aid for breast cancer screening: Views from women and health professionals. Eur J Cancer Care. 2017; 1–11. doi: 10.1111/ecc.12660 [DOI] [PubMed] [Google Scholar]
  • 46.Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol. 2020;17: 687–705. doi: 10.1038/s41571-020-0388-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Liu C, Zeinomar N, Chung WK, Kiryluk K, Gharavi AG, Hripcsak G, et al. Generalizability of polygenic risk scores for breast cancer among women with European, African, and Latinx ancestry. JAMA Netw Open. 2021;4: 1–12. doi: 10.1001/jamanetworkopen.2021.19084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Du Z, Gao G, Adedokun B, Ahearn T, Lunetta KL, Zirpoli G, et al. Evaluating polygenic risk scores for breast cancer in women of African ancestry. J Natl Cancer Inst. 2021;113: 1168–1176. doi: 10.1093/jnci/djab050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Onega T, Beaber EF, Sprague BL, Barlow WE, Haas JS, Tosteson AN, et al. Breast cancer screening in an era of personalized regimens: A conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer. 2014;120: 2955–2964. doi: 10.1002/cncr.28771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Dent T, Jbilou J, Rafi I, Segnan N, Törnberg S, Chowdhury S, et al. Stratified cancer screening: The practicalities of implementation. Public Health Genomics. 2013;16: 94–99. doi: 10.1159/000345941 [DOI] [PubMed] [Google Scholar]
  • 51.Sun L, Yang L. Cost effectiveness of urban breast cancer screening programme in China. Value in Health. 2017;20: A583–A584. doi: 10.1016/j.jval.2017.08.1049 [DOI] [Google Scholar]
  • 52.Harkness EF, Astley SM, Evans DG. Risk-based breast cancer screening strategies in women. Best Pract Res Clin Obstet Gynaecol. 2020;65: 3–17. doi: 10.1016/j.bpobgyn.2019.11.005 [DOI] [PubMed] [Google Scholar]
  • 53.Khan SA, Hernandez-Villafuerte KV, Muchadeyi MT, Schlander M. Cost-effectiveness of risk-based breast cancer screening: A systematic review. Int J Cancer. 2021; doi: 10.1002/ijc.33593 [DOI] [PubMed] [Google Scholar]
  • 54.Ozanne EM, Wittenberg E, Garber JE, Weeks JC. Breast cancer prevention: Patient decision making and risk communication in the high risk setting. Breast J. 2010;16: 38–47. 10.1111/j.1524-4741.2009.00857.x [DOI] [PubMed] [Google Scholar]
  • 55.Hagan J, Lévesque E, Knoppers BM. Influence of organizational factors on implementation of a personalized approach to breast cancer screening. Sante Publique. 2016;28: 353–361. [PubMed] [Google Scholar]
  • 56.Bravo P, Contreras A, Perestelo-Pérez L, Pérez-Ramos J, Málaga G. Looking for a more participative healthcare: sharing medical decision making. Rev Peru Med Exp Salud Publica. 2013;30: 691–697. doi: 10.17843/rpmesp.2013.304.254 [DOI] [PubMed] [Google Scholar]
  • 57.Légaré F, Adekpedjou R, Stacey D, Turcotte S, Kryworuchko J, Graham ID, et al. Interventions for increasing the use of shared decision making by healthcare professionals. Cochrane Database Syst Rev. 2018;7: CD006732. doi: 10.1002/14651858.CD006732.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Hernández-Leal MJ, Pérez-Lacasta MJ, Feijoo-Cid M, Ramos-García V, Carles-Lavila M. Healthcare professionals’ behaviour regarding the implementation of shared decision-making in screening programmes: A systematic review. Patient Educ Couns. 2021; doi: 10.1016/j.pec.2021.01.032 [DOI] [PubMed] [Google Scholar]
  • 59.Rainey L, Van Der Waal D, Jervaeus A, Donnelly LS, Evans DG, Hammarström M, et al. European women’s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: A qualitative study. BMC Cancer. 2020;20: 1–11. doi: 10.1186/s12885-020-06745-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Borgquist S, Hall P, Lipkus I, Garber JE. Towards prevention of breast cancer: What are the clinical challenges? Cancer Prev Res. 2018;11: 255–264. doi: 10.1158/1940-6207.CAPR-16-0254 [DOI] [PubMed] [Google Scholar]
  • 61.Culver JO, Bowen DJ, Reynolds SE, Pinsky LE, Press N, Burke W. Breast cancer risk communication: Assessment of primary care physicians by standardized patients. Genetics in Medicine. 2009;11: 735–741. doi: 10.1097/GIM.0b013e3181b2e5eb [DOI] [PubMed] [Google Scholar]
  • 62.Lincoln YS, Guba EG. But is it rigorous? Trustworthiness and authenticity in naturalistic evaluation. New Directions for Program Evaluation. 1986;1986: 73–84. doi: 10.1002/ev.1427 [DOI] [Google Scholar]
  • 63.Morse JM. Critical analysis of strategies for determining rigor in qualitative inquiry. Qual Health Res. 2015;25: 1212–1222. doi: 10.1177/1049732315588501 [DOI] [PubMed] [Google Scholar]
  • 64.Cypress BS. Rigor or reliability and validity in qualitative research: Perspectives, strategies, reconceptualization, and recommendations. Dimens Crit Care Nurs. 2017;36: 253–263. doi: 10.1097/DCC.0000000000000253 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Eugenio Paci

16 Nov 2021

PONE-D-21-21753Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group studyPLOS ONE

Dear Dr. Rue,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 31 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Eugenio Paci, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. When reporting the results of qualitative research, we suggest consulting the COREQ guidelines: http://intqhc.oxfordjournals.org/content/19/6/349. In this case, please consider including more information on the number of interviewers, their training and characteristics. Moreover, please provide the interview guide used as a Supplementary File.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This study was supported by the research grants ‘Personalized breast cancer screening: assessment of its feasibility and acceptability in the National Health System’ (PI17/00834) and ‘Collaboration of healthcare professionals to include shared decision-making in the breast cancer screening program’ (PI18/00773) from the Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’. Celmira Laza Vásquez received a grant from Santander Program scholarship 2020 as a predoctoral fellow at the University of Lleida. The funders did not participate in the study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.”

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“MR

PI17/00834: Personalized breast cancer screening: assessment of its feasibility and acceptability in the National Health System. Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’https://www.isciii.es

MCL

PI18/00773: Collaboration of healthcare professionals to include shared decision-making in the breast cancer screening program.Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’ https://www.isciii.es

CLV Santander Program scholarship 2020:  predoctoral fellow at the University of Lleida

The funders did not participate in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

This is an important qualitative research considering the main aspects and problems related to the future, possible implementation of personalized approaches in cancer screening. The presentation is interesting with reference to the debate on this issue. Perhaps the manuscript is long. I will suggest to the authors to reduce the length, if possible. The discussion session considered as one of the most relevant issue the reduction of the interval in lower risk women. This attitude is certainly a manifestation of fear and uncertainty. However, I invite to consider the case of cervical cancer screening where the change from pap-smear to Hpv-testing gave the possibility to change from 3 to 5 years interval. The change of type of technology as a new, innovative screening test possibly facilitated the acceptance of a longer interval.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: General comments

The paper affords an interesting and important issue with the appropriate method.

In general, the paper can be shortened since many parts of the introduction are reported similarly in the discussion; also the results are redundant in some parts of the text that simply repeats the quotes reported in the tables.

I suggest to check better the classification of quotes in the four tables and also their relevance for the “barriers” and “facilitators”: in some cases I found the classification arbitrary or even incorrect.

Please check the text: table 2 is placed in the wrong place and table 1S is missing.

There are many typos and incomplete sentences; I cannot be sure since I am not native English, but probably there are also some grammar errors (for example nouns used as adjectives should be singular, the use of comas and/or “and” in list is misleading).

Specific comments

Abstract

Results: the list of facilitators is a mix of existing factors (that should be used or emphasized) and some actions or interventions that should be present but are not in place now (example commitment of policy makers; training of health care workers). Can you try to write the sentence to explain it?

Conclusion: the sentence “to our knowledge…” (lines 51-3) is not useful for an abstract (I suggest to drop it even in the text).

Introduction

It can be shortened, for example, the paragraph from line 112 to line 135 can be dropped since it is reported in the discussion in the same way; also lines 138-141 are in the discussion. Why are you introducing shared decision making? I did not find this topic in the discussion groups (maybe because table S1 is missing).

Line 89: “screening personalization is effective” I suggest to change the sentence in “models forecast that personalised screening may increase health benefits and be more efficient”

Line 150: the intervention you are proposing to the discussion would be not “clinical practice”, but preventive practice.

Methods

Line 193-195: please explain why a focus group does not allow positioning of different profiles.

Line 197: I suppose “table 2” should be table S1 (that is missing in the pdf), while table two refers to the first paragraph of the results.

Lines 239-242: is this part necessary? This sentence repeats the objective.

Results

In the first paragraph, please introduce also the final subheading about the “organizational proposals”, this would help the reader.

Table 2: first and second barriers seem the same to me. Furthermore, this issue may be also a problem related to the health professionals. “facilitators: benefits of personalized screening” the point of younger women is much more specific and deserves a specific title.

table 4: “cost of measuring the risk” In the quotes I see costs of measuring and communicating risk and of surveillance.

table 5: “budget allocation” why is this different from the costs and sustainability of the program? I do not see a cost opportunity point of view in these quotes, but they are rather similar to that in table 4 about costs

please check again the classification of the sentence in your research group

Line 318: I suggest to name this paragraph using the same words used in the initial paragraph of the results where you introduced it.

Discussion

lines 536-537: the predictive value of available SNPs is different in different ancestries, see Liu C eta alt JAMA network open 2021 and Du Z et al JNCI 2021.

Conclusion

Lines 667-670: I suggest to drop it at all, but definitely it is not a conclusion.

Reviewer #2: This study explores the barriers and facilitators, as perceived by healthcare professionals, for implementing risk-based breast screening programme in Spain.

This is a timely topic. Overall the study is well thought and clearly written. I enjoyed reading it.

Few minor points:

To understand the context and have an insight into the responses of the participants, it will be very helpful to add:

• short introduction to the organization of the existing age-based screening programme, explaining the role of the primary care physicians

• the information the participants were provided about risk-based screening

For example, on p19 and p31, ‘…since the potential implementation of risk-based breast screening will require extensive changes in current practice…’ and ‘…substantial efforts will be required to abandon a screening programme in use for more than 30 years and introduce a new one that still presents uncertainties…’ So what is the current structure and what changes are anticipated with risk-based screening? If the expected changes are assumed changes, and presented to the participants as changes needed, then this would influence the perspective of the participants on the perceived barriers and facilitators.

Looking into some of responses quoted such as ‘…genomic test cannot be performed at home by the user, so they need assistance’ [DG2P3]; ‘…in large European populations they (SNPS) are not yet validated’ [DG3P6]; ‘…all women over 40 years have to do a mamogram’[DG1P3], etc, it is not clear whether these reflect the information provided to the participants or misconceptions of the participants (e.g. genetic testing). If the latter, then in itself informative that not knowing much about the field generates fear and resistance to change. Worth the authors expanding on these points.

The category of women’s perceptions is interesting, it reflects the perception of the HCPs of the perception of women. In fact, how much these reflect HCPs own perceptions and their concerns but articulated from women’s point of view.

Helpful to expand if there was any discussion of the HCPs perception of ‘how to’ overcome the barriers, how to get policy commitment?

It’s unfortunate that the question on the perception of the HCPs on how should the personalised screening programme to be organized.

P29, ‘…there is consensus on incorporating personal and family history, breast density, benign breast disease and lifestyle factors…’ Is there a consensus to incorporate all these risk factors in population-based screening programme or is there evidence that comprehensive risk assessment model improves the risk prediction?

In the Discussion section, sometimes it is not clear what the authors are recommending based on the findings vs. based on their summary of the literature. As one of the several examples, ‘Thus, health professionals seemed to have a good predisposition towards risk-based screening. However, it is essential that they know the results of the research and understand the statistics of early detection to avoid misleading and potentially harmful recommendations [18].’

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: paolo giorgi rossi

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Feb 4;17(2):e0263788. doi: 10.1371/journal.pone.0263788.r002

Author response to Decision Letter 0


24 Jan 2022

The authors would like to thank the editor and reviewers for their comments, as their contributions have considerably improved the new version. Suggested modifications have been made to the text, which are highlighted in the file 'Revised Manuscript with Track Changes'. You can find a specific answer to each comment below:

Editorial team We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“MR: PI17/00834: Personalized breast cancer screening: assessment of its feasibility and acceptability in the National Health System. Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’ https://www.isciii.es

MCL: PI18/00773: Collaboration of healthcare professionals to include shared decision-making in the breast cancer screening program.Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) ‘Una manera de hacer Europa’ https://www.isciii.es

CLV: Santander Program scholarship 2020: predoctoral fellow at the University of Lleida

MJH-L: European Regional Development Fund (ERDF). European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 713679 from the Universitat Rovira i Virgili (URV).

The funders did not participate in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Answer: We have added a source of funding for Maria José Hernández-Leal. We forgot to include it in the first submission. Otherwise, we agree on the above specified Funding Statement and we have removed the study’s funding information from the manuscript.

Editorial team 4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Answer: The entire reference list has been reviewed and no retracted papers have been cited.

Additional Editor Comments:

This is an important qualitative research considering the main aspects and problems related to the future, possible implementation of personalized approaches in cancer screening. The presentation is interesting with reference to the debate on this issue. Perhaps the manuscript is long. I will suggest to the authors to reduce the length, if possible. The discussion session considered as one of the most relevant issue the reduction of the interval in lower risk women. This attitude is certainly a manifestation of fear and uncertainty. However, I invite to consider the case of cervical cancer screening where the change from pap-smear to Hpv-testing gave the possibility to change from 3 to 5 years interval. The change of type of technology as a new, innovative screening test possibly facilitated the acceptance of a longer interval.

Answer: We have reduced the length of the manuscript. In the introduction, we have supressed several lines in the paragraph that starts with “Several studies have addressed the perspectives…”. Nevertheless, we have added some sentences to clarify some aspects that the reviewers rose up (e.g. the organization of screening in Spain or the role of primary care physicians).

With respect ot the case of cervical cancer, we have added the following sentences at the end of the third paragraph in the Barriers and facilitators related to women subsection of the Discussion: A research synthesis on factors associated to the acceptability of human papillomavirus HPV testing for cervical cancer found that strategies that increase women’s knowledge and efforts to increase health care providers’ awareness might also increase acceptability of wider screening intervals (Tatar, 2018).

Reviewers’ comments

Reviewer #1 (R#1): General comments The paper affords an interesting and important issue with the appropriate method. In general, the paper can be shortened since many parts of the introduction are reported similarly in the discussion; also the results are redundant in some parts of the text that simply repeats the quotes reported in the tables.

Answer: Thank you, very much. The introduction has been shortened. We have eliminated some of the quotes in the tables because of redundancy.

R#1 I suggest to check better the classification of quotes in the four tables and also their relevance for the “barriers” and “facilitators”: in some cases I found the classification arbitrary or even incorrect.

Answer: The reviewer is right. We have reviewed the tables and made changes in order to increase the correspondence between them and the assigned barriers and facilitators. In some cases it is difficult, because the same quote refers to more than one theme.

R#1 Please check the text: table 2 is placed in the wrong place and table 1S is missing.

Answer: Thank you, we have moved Table 2 to the right place and added table S1.

R#1 There are many typos and incomplete sentences; I cannot be sure since I am not native English, but probably there are also some grammar errors (for example nouns used as adjectives should be singular, the use of comas and/or “and” in list is misleading).

Answer: The new version of the manuscript has been revised by a native English speaker.

R#1 Specific comments Abstract Results: the list of facilitators is a mix of existing factors (that should be used or emphasized) and some actions or interventions that should be present but are not in place now (example commitment of policy makers; training of health care workers). Can you try to write the sentence to explain it?

Answer: The last sentence in the results section in the abstract now states that the listed interventions will be required. We have moved “commitment of policy makers” from the previous sentence, which includes actions or interventions that are in place now or that there is evidence, to the last sentence.

R#1 Conclusion: the sentence “to our knowledge…” (lines 51-3) is not useful for an abstract (I suggest to drop it even in the text).

Answer: The sentence has been eliminated from the abstract and moved to another paragraph in the Discussion section, in the text.

R#1 Introduction It can be shortened, for example, the paragraph from line 112 to line 135 can be dropped since it is reported in the discussion in the same way; also lines 138-141 are in the discussion. Why are you introducing shared decision making? I did not find this topic in the discussion groups (maybe because table S1 is missing).

Answer: The introduction has been shortened. The paragraph from line 112 to line 135 has been summarized. We introduced shared decision-making because we think that personalized screening needs the consensus of women and health professionals. As the reviewer suggests the fact that table S1 was missing, made it difficult to understand why we introduced shared decision-making.

R#1 Line 89: “screening personalization is effective” I suggest to change the sentence in “models forecast that personalised screening may increase health benefits and be more efficient”

Answer: We agree with the reviewer. We have modified the sentence: “… with personalized screening, the gain in quality adjusted life years would be higher at a lower cost, compared with the standard one-size-fits-all strategy.”

R#1 Line 150: the intervention you are proposing to the discussion would be not “clinical practice”, but preventive practice.

Answer: We use “clinical practice” in the broad sense. There are many clinical guidelines on screening, as well as sections in journals called clinical practice that include articles on screening.

R#1 Methods Line 193-195: please explain why a focus group does not allow positioning of different profiles.

Answer: In the second paragraph of the Data Collection section we have explained the advantages of discussion groups when exploring the views of health professionals on risk based breast cancer screening and its implementation in the Spanish NHS. We have intended to present the discussion group technique as an open and less directive form of the inquiry than the focus group.

R#1: Line 197: I suppose “table 2” should be table S1 (that is missing in the pdf), while table two refers to the first paragraph of the results.

Answer: The reviewer is correct, we forgot to submit Table S1 and we put Table 2 in the wrong place. We have corrected both errors in the new version of the manuscript.

R#1: Lines 239-242: is this part necessary? This sentence repeats the objective.

Answer: We have deleted the paragraph.

R#1 Results In the first paragraph, please introduce also the final subheading about the “organizational proposals”, this would help the reader.

Answer: Done

R#1 Table 2: first and second barriers seem the same to me.

Answer: The reviewer is right. Both barriers are similar, although rejecting recommendations does not imply necessarily resistance to change. We have changed the quotes in the barrier “resistance to change”.

R#1 Furthermore, this issue may be also a problem related to the health professionals. “facilitators: benefits of personalized screening” the point of younger women is much more specific and deserves a specific title.

Answer: We have added “for young women” in the title "benefits of a ris-based program, in table 2.

R#1 table 4: “cost of measuring the risk” In the quotes I see costs of measuring and communicating risk and of surveillance.

Answer: We have shortened the second quote and maintained the title of the section.

R#1 table 5: “budget allocation” why is this different from the costs and sustainability of the program? I do not see a cost opportunity point of view in these quotes, but they are rather similar to that in table 4 about costs please check again the classification of the sentence in your research group

Answer: The reviewer is right. We have changed the quotes so now they seem more adequate to us.

R#1 Line 318: I suggest to name this paragraph using the same words used in the initial paragraph of the results where you introduced it.

Answer: We have changed the section title to “Barriers and facilitators related to implementing a risk-based screening program”.

R#1 Discussion lines 536-537: the predictive value of available SNPs is different in different ancestries, see Liu C eta alt JAMA network open 2021 and Du Z et al JNCI 2021.

Answer: We have added a sentence that includes both references.

R#1 Conclusion Lines 667-670: I suggest to drop it at all, but definitely it is not a conclusion.

Answer: We have moved it to the Strengths and Limitations section of the Discussion.

Reviewer #2 (R#2) This study explores the barriers and facilitators, as perceived by healthcare professionals, for implementing risk-based breast screening programme in Spain.

This is a timely topic. Overall the study is well thought and clearly written. I enjoyed reading it.

Answer: Thank you very much.

R#2 Few minor points: To understand the context and have an insight into the responses of the participants, it will be very helpful to add:

• short introduction to the organization of the existing age-based screening programme, explaining the role of the primary care physicians

• the information the participants were provided about risk-based screening

For example, on p19 and p31, ‘…since the potential implementation of risk-based breast screening will require extensive changes in current practice…’ and ‘…substantial efforts will be required to abandon a screening programme in use for more than 30 years and introduce a new one that still presents uncertainties…’ So what is the current structure and what changes are anticipated with risk-based screening? If the expected changes are assumed changes, and presented to the participants as changes needed, then this would influence the perspective of the participants on the perceived barriers and facilitators.

Answer: 1) A brief introduction to the existing screening program in Spain has been added to the 6th paragraph of the introduction. We also have included a new paragraph in the introduction (8th) that describes the recommendations of the Spanish Family and Community Medicine for primary care physicians.

2) Participants received information about risk-based screening before starting the discussion. The supplementary information file, that we forgot to append when we submitted the manuscript, contains the details of the discussion guide. There, we say that two members of the research group presented a proof of concept study on the feasibility and acceptability of risk-based screening, carried out by the study team. We have added a sentence with the details in section Data Collection of the manuscript with a reference to the study protocol.

The reviewer is right when she or he says that the perspective of the participants on perceived barriers and facilitators may have been influenced by how changes needed for risk-based screening were presented. We have added a limitation based on this comment in the Discussion section.

R#2 Looking into some of responses quoted such as ‘…genomic test cannot be performed at home by the user, so they need assistance’ [DG2P3]; ‘…in large European populations they (SNPS) are not yet validated’ [DG3P6]; ‘…all women over 40 years have to do a mamogram’[DG1P3], etc, it is not clear whether these reflect the information provided to the participants or misconceptions of the participants (e.g. genetic testing). If the latter, then in itself informative that not knowing much about the field generates fear and resistance to change. Worth the authors expanding on these points.

Answer: We think that both the information provided -which was scarce due to time limitations- and some misconceptions of the participants contributed to generate fear and resistance to change. A recent systematic review by Bellhouse et al. indicates that primary care providers when assessing breast cancer risk focused on collection of family history and provision of support for women at increased risk. The authors mention that insufficient education/training and perceived discomfort were the most commonly endorsed barriers reported for risk assessment and risk-reducing medication. Nevertheless, the integration of risk assessment and management tools into practice software or access to web-based applications would facilitate the change, as happened for cardiovascular risk assessment and management.

We have included these findings in different paragraphs of the discussion.

R#2 The category of women’s perceptions is interesting, it reflects the perception of the HCPs of the perception of women. In fact, how much these reflect HCPs own perceptions and their concerns but articulated from women’s point of view.

Answer: Reviewer #2 is right. We have not measured Spanish women’s views on risk-based screening and therefore we don’t know how much HCP’s perceptions reflect those of women. But, when Rainey et al. (2018) explored whether professionals views of acceptability of risk-based breast cancer screening and prevention were in line with those of eligible women, in the United Kingdom, Sweden and the Netherlands, the answer was positive. Also, European women’s perceptions of the implementation and organisation of risk-based breast cancer screening and prevention, were consistent with those of professionals (Rainey 2020).

We have slightly modified a couple of sentences in this section of the Discussion, to highlight this agreement.

R#2

Helpful to expand if there was any discussion of the HCPs perception of ‘how to’ overcome the barriers, how to get policy commitment?

Answer: Participants, during the discussion, proposed several facilitators to overcome the barriers. Unfortunately, some of the issues, such as how to achieve political compromise, were not discussed in sufficient depth due to lack of time.

R#2

It’s unfortunate that the question on the perception of the HCPs on how should the personalised screening programme to be organized.

Answer: Yes, that is true.

R#2 P29, ‘…there is consensus on incorporating personal and family history, breast density, benign breast disease and lifestyle factors…’ Is there a consensus to incorporate all these risk factors in population-based screening programme or is there evidence that comprehensive risk assessment model improves the risk prediction?

Answer: The reviewer made a good point. Probably there is not yet consensus on incorporating all these risk factors in population-based screening programs. Since a few lines before we had written "The network highlights how risk stratification has improved with the use of comprehensive models ...", we have shortened the sentence to: "Although research is still ongoing to assess the clinical utility of PRS for population screening programs, Yanes et al. point out that polygenic testing is already being implemented in specialist familial cancer clinics...".

R#2 In the Discussion section, sometimes it is not clear what the authors are recommending based on the findings vs. based on their summary of the literature. As one of the several examples, ‘Thus, health professionals seemed to have a good predisposition towards risk-based screening. However, it is essential that they know the results of the research and understand the statistics of early detection to avoid misleading and potentially harmful recommendations [18].’

Answer: We have tried to clarify which recommendations come from our study and which come from the literature.

Attachment

Submitted filename: Main_1.0_Response_to_Reviewers_Plos.docx

Decision Letter 1

Eugenio Paci

27 Jan 2022

Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group study

PONE-D-21-21753R1

Dear Dr. Rue,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Eugenio Paci, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for the work done. All comments have been addressed.

Reviewers' comments:

Acceptance letter

Eugenio Paci

28 Jan 2022

PONE-D-21-21753R1

Views of health professionals on risk-based breast cancer screening and its implementation in the Spanish National Health System: A qualitative discussion group study

Dear Dr. Rué:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Eugenio Paci

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Discussion groups guide.

    (DOCX)

    Attachment

    Submitted filename: Main_1.0_Response_to_Reviewers_Plos.docx

    Data Availability Statement

    Data consists of recorded group discussions and the corresponding transcriptions. Languages used were Catalan and Spanish. Data cannot be shared publicly because we did not ask participants' consent to share the recorded materials. Data are available from the The Drug Research Ethics Committee of the University Hospital Arnau de Vilanova at Lleida (contact via e-mail ceim.lleida.ics@gencat.cat) for researchers who meet the criteria for access to confidential data.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES